Research programme: embryonic stem cell therapies - ES Cell International

Drug Profile

Research programme: embryonic stem cell therapies - ES Cell International

Alternative Names: ESI-014; ESI-017; ESI-035; ESI-049; ESI-051; ESI-053

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ES Cell International
  • Developer BioTime; ES Cell International; University of California at Irvine
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Huntington's disease
  • No development reported Diabetes mellitus; Heart failure

Most Recent Events

  • 17 Jan 2018 BioTime has patent protection for Pluripotent cell technology in USA, Japan, Singapore, India and Europe
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in Singapore (Parenteral, Implant)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in Singapore (Parenteral, Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top